| Name | Brentuximab |
|---|
| Description | Brentuximab is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Oh Y, et al. Part II: Prognosis and management. J Am Acad Dermatol. 2021 Nov;85(5):1093-1106. |
| No Any Chemical & Physical Properties |